Skip to Content
MilliporeSigma
All Photos(3)

Documents

HCCBP2MAG-58K

Millipore

MILLIPLEX® Human Circulating Cancer Biomarker Magnetic Bead Panel 2 - Cancer Multiplex Assay

Circulating Cancer Biomarker Bead-Based Multiplex Assays using the Luminex technology enables the simultaneous analysis of multiple oncology biomarkers in various tumor types in human serum, plasma and cell culture samples.

Sign Into View Organizational & Contract Pricing

UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84

Quality Level

species reactivity

human

manufacturer/tradename

Milliplex®

assay range

accuracy: 92-107%
standard curve range: 0.01-50 ng/mL
(Extracellular matrix protein 1)

standard curve range: 0.48-2,000 ng/mL
(All other biomarkers)

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex xMAP)

shipped in

wet ice

General description

Circulating cancer biomarkers give insight beyond intracellular oncogenesis and into how the body responds to the presence of a tumor, the dysregulation of homeostasis, and the relationship between a tumor and its environment. Multianalyte panels have become essential tools that enable researchers to measure cancer biomarkers simultaneously, teasing out these relationships and applying them to understand tumor biology.

MILLIPLEX® Circulating Cancer Biomarker Panel 2 is a 4-plex kit that can be used for the simultaneous quantification of any or all of the following analytes in serum, plasma, tissue/cell lysate and culture supernatant samples: Extracellular matrix Protein 1 (ECM1), Antithrombin III, Vitamin D binding protein, and Complement Factor H (CFH). This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Circulating Cancer

Application

  • Analytes: Antithrombin III, Complement Factor H (CFH), Extracellular matrix Protein 1 (ECM1), Vitamin D binding protein
  • Recommended Sample Type: Human serum, plasma or tissue/cell culture supernatants or lysates
  • Note: Serum has a thrombin/antithrombin III complex bound to vitronectin. To accurately quantify antithrombin III concentrations we recommend using plasma samples because they lack the vitronectin/thrombin/antithrombin complex.
  • Recommended Sample Dilution: 25 μL of a 1:10,000 dilution of plasma or serum, or 25 μL of tissue/cell culture sample diluted in an appropriate control medium (dilution factors may vary)
  • Assay Run Time: Overnight (16-18 hours) at 2-8°C
  • Research Category: Cancer

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

Components

Human Circulating Cancer Biomarker Panel 2 Standard (HCC-8058-2)

Human Circulating Cancer Biomarker Panel 2 Quality Controls 1 and 2 (HCC-6058-2)

Set of one 96-Well Plate with 2 Sealers

Bead Diluent (LBD-4)

Assay Buffer (L-AB)
Note: Contains 0.08% Sodium Azide

10X Wash Buffer (L-WB)
Note: Contains 0.05% Proclin

Human Circulating Cancer Biomarker Panel 2 Detection Antibodies (HCC-1058)

Streptavidin-Phycoerythrin (L-SAPE 6)

Other Notes

Sensitivity: Refer to kit protocol for sensitivities of individual biomarkers.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

wgk_germany

WGK 3


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ginette Tardif et al.
Arthritis research & therapy, 24(1), 120-120 (2022-05-24)
Osteoarthritis (OA) is a slowly developing and debilitating disease, and there are no validated specific biomarkers for its early detection. To improve therapeutic approaches, identification of specific molecules/biomarkers enabling early determination of this disease is needed. This study aimed at

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service